Fucoidan-based Micelles As P-selectin Targeted Carriers for Synergistic Treatment of Acute Kidney Injury.

Gaofeng Shu,Chenying Lu,Zhixian Wang,Yuyin Du,Xiaoling Xu,Min Xu,Zhongwei Zhao,Minjiang Chen,Yiyang Dai,Qiaoyou Weng,Shiji Fang,Kai Fan,Di Liu,Yongzhong Du,Jiansong Ji
DOI: https://doi.org/10.1016/j.nano.2020.102342
2021-01-01
Nanomedicine
Abstract:Acute kidney injury (AKI) is a life-threatening disease without effective treatment. The utilization of curcumin (Cur) for the treatment of AKI is still facing challenges due to its poor water-solubility and low bioavailability. Herein, kidney-targeted octenyl succinic anhydride-grafted fucoidan loaded with Cur (OSA-Fucoidan/Cur) was fabricated for synergistic treatment of AKI. It was found that OSA-Fucoidan/Cur micelles had a sustained drug release behavior and excellent physicochemical stability. Cellular uptake studies demonstrated that the specific binding between fucoidan and P-selectin overexpressed on H2O2-stimulated HUVECs contributed to the higher internalization of OSA-Fucoidan/Cur micelles by the cells. In addition, OSA-Fucoidan micelles exhibited an ideal kidney-targeted characteristic in lipopolysaccharide (LPS)-induced AKI mice. In vivo studies showed that the combination of Cur and OSA-Fucoidan endowed the OSA-Fucoidan/Cur micelles with synergistically anti-inflammatory and antioxidant abilities, thereby largely enhancing the therapeutic efficacy of AKI. Therefore, OSA-Fucoidan/Cur micelles may represent a potential kidney-targeted nanomedicine for effective treatment of AKI.
What problem does this paper attempt to address?